Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneousinjections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
The conversation is about a hair loss treatment plan involving finasteride, minoxidil, microneedling, GHK-CU injections, Nizoral shampoo, and RU58841. The user is advised to start with a simpler regimen to minimize side effects and assess effectiveness before adding more treatments.
The conversation is about a user making a homemade topical dutasteride solution to use alongside testosterone replacement therapy (TRT) and oral dutasteride. The user aims to reduce DHT locally at the testosterone injection site and on the scalp.
SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.
Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Prolactin's role in immune system's antitumor activity raises safety concerns for HMI-115.